Roche reports Phase 2 results for petrelintide, another amylin analogue
OtherP1Primary public evidenceSponsor press release
On 5 March 2026 Roche announced topline Phase 2 (ZUPREME-1) results for petrelintide in 493 adults with obesity or overweight. The sponsor reported mean weight reduction of up to 10.7% at week 42 against 1.7% with placebo, and adverse-event discontinuation of 4.8% at the most effective dose against 4.9% with placebo.
up to -10.7% vs -1.7%
Mean body weight change at week 42, petrelintide vs placebo (efficacy estimand)
4.8% vs 4.9%
Stopped treatment because of adverse events, most effective dose vs placebo
Background and context
How the trial was designed
ZUPREME-1 is registered as a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial. It compares five doses of once-weekly petrelintide with placebo in 493 adults at sites in the United States, Poland and Romania. Treatment lasted 42 weeks, followed by a nine-week safety period. Adults needed a BMI of at least 30, or at least 27 with hypertension or dyslipidemia, and people with diabetes were excluded.
Reading the announced figure against the registry
The registry lists percent change in body weight at week 28 as the primary endpoint. The week 42 weight change quoted in the release is a registered secondary measure. The registry names Zealand Pharma as the sponsor, while the release cited here is from Roche. It lists the study as completed, with no results posted, and primary completion in September 2025.
Trial record: ClinicalTrials.gov NCT06662539, read on 2026-10-15.
